top of page

Second Generation Drugs "Zycords" – Patent GRANTED!

Concenter Biopharma Ltd. (and parent company Silkim Pharma Ltd.), are proud to announce another acceptance of the Patent covering the Second Generation of the anti-inflammatory and anti-diabetic drug candidate – the “Zycords”.

Previously developed - Zygosids, are a family of drug candidates, with IP protected in numerous jurisdictions around the world. The first in man clinical trial assessing the therapeutic effect of Zygosid-50 against Type 2 Diabetes is now in process at the Sheba Medical Center.

Now, the Second Generation of the drug candidates - "ZYCORDS" - with analogous mechanisms of action, is starting the safety and efficacy trials.

The priority patent of this family is 12/2014 and it is being examined in jurisdictions worldwide. Now, the Indian Patent Office has recognized the Zycords as a family of new chemical entities (NCEs) and the appropriate patent was GRANTED (12/2020). The Claims of this acceptance protect the composition of matter of the Zycords — this new family of drugs, and protect their use in medicine and pharmacy, in a broad variety of modes of their administration to a patient in need.

Patent Stamp


Logo concenter biopharma.jpg

Hi, thanks for stopping by!

Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications. 


Our PLATFORM is the result of extensive investigation of animal models of human diseases.

Let the news
come to you.

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
bottom of page